Navigation Links
MedImmune Expands R&D Capacity with New Research Facility in Cambridge, U.K.
Date:10/16/2008

- Building Named After 1982 Nobel Prize Winner for Chemistry, Sir Aaron

Klug -

CAMBRIDGE, England, Oct. 16 /PRNewswire/ -- MedImmune today announced the opening of a new, biologics research and development (R&D) facility in Cambridge, the United Kingdom. Named after the 1982 Nobel Prize Winner for Chemistry, the Aaron Klug Building is a major expansion of MedImmune's existing Granta Park site, further cements the region as a major R&D centre for the company, and provides additional laboratory space for MedImmune's growing scientific staff in Cambridge.

The Aaron Klug Building is a 92,000-square-foot facility containing state-of-the-art laboratories. The facility provides MedImmune with capacity to significantly increase the number of candidate drugs that it can develop each year in order to meet R&D goals.

The expansion forms a key part of MedImmune's growth strategy. Following its acquisition by AstraZeneca in June 2007, MedImmune was consolidated with the former Cambridge Antibody Technology business, along with other areas of biological research being conducted elsewhere within AstraZeneca. Now as AstraZeneca's global biologics unit, MedImmune plays a significant role in AstraZeneca's strategic growth plans -- the aim is to deliver an average of one new biologic product per year from 2013.

Jane Osbourn, site leader and vice president of research, Cambridge, said: "Today, MedImmune has one of the largest and most diverse biologics product pipelines in the biotech and pharmaceutical industries. We want to maximise our potential to develop new and better medicines, so adequate space and resource for R&D is a real priority for us.

"Our experience and expertise in Cambridge means the U.K. team plays a central role in MedImmune's global research activity. The Aaron Klug Building is critical to allowing us to fulfill this role and to achieve our goal of significantly increasing our drug development capabilities," Osbourn added.

The new facility is being inaugurated today with the unveiling of a commemorative plaque by honoured guest, Sir Aaron Klug.

The Aaron Klug Building forms part of MedImmune's wider expansion of its European operations. Its opening follows the recent refurbishment and expansion of one of the company's major production sites in Nijmegen in the Netherlands, where products such as Synagis(R) (palivizumab) and Ethyol(R) (amifostine) are prepared for distribution. Completed in early 2008, the newly refurbished site is capable of producing up to 10 discrete products each year, equating to 6.5 million vials.

About MedImmune

MedImmune is a leading innovation-focused biotechnology company whose mission it is to provide better medicines to patients, new medical options for physicians and rewarding careers to employees. Dedicated to advancing science and medicine to help people live better lives, the company is focused on infection, oncology, respiratory disease and inflammation, cardiovascular/ gastrointestinal disease and neuroscience. Headquartered in Gaithersburg, Maryland, MedImmune has approximately 3,000 employees worldwide and is the wholly owned biologics business for AstraZeneca plc (LSE: AZN.L, NYSE: AZN). For more information, visit MedImmune's website at http://www.medimmune.com.


'/>"/>
SOURCE MedImmune
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. MedImmune Presents Data at AAP National Conference & Exhibition Demonstrating Burden of RSV Disease
2. Pinnacle Biologics Announces Stock Purchase Agreement With MedImmune
3. MedImmunes Brian Rosen Honored by Montgomery County Chamber at 49th Annual Awards Dinner
4. Depth of MedImmunes Respiratory Disease Research Program Highlighted at Annual Meeting of the American Thoracic Society
5. MedImmune Fortifies Strategic Scientific Portfolio Management and International Leadership With New Executive Appointments
6. MedImmune Presents Data Highlighting its Progressive Oncology Portfolio at Annual Meeting of the American Association For Cancer Research
7. Seneca Valley High School Student Receives Science Award From MedImmune
8. MedImmune Strengthens Key Leadership Functions to Further Support Recently Expanded, Rapidly Advancing Product Portfolio
9. MedImmune Submits Biologics License Application to FDA for Motavizumab
10. MedImmune Broadens Focus of Venture Capital Fund to Include New Therapeutic Areas
11. MedImmune Announces Seven Key Promotions and New Hires
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/18/2017)... Research and Markets has announced the addition of the "Nanobiotechnology ... ... separate comprehensive analytics for the US, Japan , ... and forecasts are provided for the period 2015 through 2022. Also, ... and analytics are derived from primary and secondary research. This report ...
(Date:2/17/2017)... ... February 17, 2017 , ... Academy of Model Aeronautics ... leading maker of unmanned aircraft systems (UAS), are launching a joint program to ... effectively, and support educational outreach efforts. , AMA and DJI will collaborate on ...
(Date:2/16/2017)... 16, 2017  ImMAGE Biotherapeutics (OTCMKTS: IMMG), an early-stage biotechnology ... a better treatment for triple negative breast cancer (TNBC), announced ... France program. The YEi Start in ... to help entrepreneurs grow their business in France ... American companies selected to complete an intensive one week immersion ...
(Date:2/16/2017)... -- Research and Markets has announced the ... report to their offering. ... The study scope ... plasmids, chassis organisms, synthetic cells, production systems), enabling technologies ... and specialty media) and enabled technologies (biofuels, chemicals, pharmaceuticals, ...
Breaking Biology Technology:
(Date:2/8/2017)... The biometrics market has reached a ... organizations, desires to better authenticate or identify users ... challenge questions), biometrics is quickly working its way ... is driven by use cases, though there traditionally ... uses cases, with consumer-facing use cases encompassing authentication, ...
(Date:2/7/2017)... , Feb. 7, 2017 Zimmer Biomet Holdings, ... musculoskeletal healthcare, will present at the LEERINK Partners 6th ... Palace Hotel on Wednesday, February 15, 2017 at 10 ... of the presentation can be accessed at http://wsw.com/webcast/leerink28/zbh ... the conference via Zimmer Biomet,s Investor Relations website at ...
(Date:2/3/2017)... Feb. 3, 2017  Texas Biomedical Research Institute announced that ... Larry Schlesinger as the Institute,s new President and CEO. ... May 31, 2017. He is currently the Chair of the ... Center for Microbial Interface Biology at Ohio State University. ... new President and CEO of Texas Biomed," said Dr. ...
Breaking Biology News(10 mins):